Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Full approval is based on a global phase III trial which found casirivimab and imdevimab reduced hospitalisation or death by 70% in high-risk non-hospitalised patients Basel, 20 July 2021 - Roche...
-
Las Vegas, USA, July 19, 2021 (GLOBE NEWSWIRE) -- Lupus Nephritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Lupus Pipeline Comprising a Broad Spectrum of Molecular Targets ...
-
SAN CARLOS Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
-
Visiongain has published a new report on Allergy Treatment Market Report to 2031: Forecasts By Type (Eye Allergy, Skin Allergy, Food Allergy, Asthma, Rhinitis, and Others), By Treatment (Anti-Allergy...
-
Übernahme stärkt BioNTechs Zelltherapie-Pipeline durch Beschleunigung des Forschungs- und Entwicklungsprogramms für individualisierte Neoantigen-TCR-Zelltherapien für solide Tumore sowie den Ausbau...
-
Deal strengthens BioNTech’s cell therapy pipeline by accelerating individualized solid tumor Neoantigen TCR cell therapy research and development program and adding manufacturing footprint in North...
-
WILMINGTON, Del., July 19, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Martin Babler to its...
-
Final analysis from the phase IIIb STASEY study, including data from 193 people with haemophilia A, further support the benefit/risk profile of Hemlibra, with no new safety signals identified1STASEY...
-
Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Global Head and Neck Cancer Therapeutics Market By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others), By Treatment Type, By Disease Indication,...
-
NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today...